Phase 4 N=20 Topical Psoriasis Study for Patients Receiving Biologic Therapy
Psoriasis
Primary: Psoriasis Severity — 4.25 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=352 Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
Psoriasis
Primary: Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at…
Phase 3 N=174 Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement
Psoriasis
Primary: Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From…
Phase 2 N=227 A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis
Plaque Psoriasis
Primary: Percentage of Participants Who Achieved Greater Than or Equal to (>=) 75 Percent (%) Improvement From Baseline in Psoriasis Area Severity Index Score (PASI-75) at LTE…
Phase 4 N=100 Apremilast in Palmo-Plantar Psoriasis
Palmo-plantar Psoriasis
Primary: Palmoplantar Psoriasis Physician Global Assessment (PPPGA) of 0 or 1 — 7; 2 Participants
Phase 3 N=1,647 Plaque Psoriasis Efficacy and Safety With Secukinumab
Plaque Psoriasis
Primary: Maintenance of PASI 90 Response at Week 52 in Participants With a PASI 90 Response at Week 24 — 552; 496 Participants — p=0.1499
Phase 2 N=81 Topical CP-690,550 For Chronic Plaque Psoriasis
Psoriasis
Primary: Percent Change From Baseline in Target Plaque Severity Score (TPSS) at Week 4 — 2.38; -4.76; 2.48; -4.17 Percent Change
Phase 2 N=129 A Study to Determine the Efficacy of ZPL-3893787 in Subjects With Plaque Psoriasis
Psoriasis
Primary: Percent Change From Baseline in Psoriasis Assessment of Severity Index (PASI) at Week 12 — -28.043; -37.361 percentage change — p=0.8495
Phase 2 N=24 A Psoriasis Plaque Test Study With LEO 90100 Cutaneous Spray, Ointment, in Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Absolute Change in Total Clinical Score (TCS) of Clinical Signs (Sum of Erythema, Scaling and Infiltration) at End of Treatment Compared to Baseline — -6.00; -4.96…
Phase 3 N=237 Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab
Palmoplantar Pustular Psoriasis
Primary: Percentage of Participants With ppPASI 75 Response at Week 16 (Period 1) — 17.5; 26.6; 14.1 percentage of participants — p=0.5722
Phase 2 N=9 Acitretin and Etanercept in Psoriasis
Psoriasis
Primary: Percent of Patients Achieving PASI 75 at 6 Months After the Addition of Acitretin Therapy — 12.5 percent
Phase 4 N=29 Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis
Plaque Psoriasis
Primary: Number of Participants Maintaining Psoriasis Area Severity Index Score (PASI) 75 at Week 36 — 4; 2 participants
Phase 4 N=81 Vascular Inflammation in Psoriasis - Extension Study
Psoriasis · Cardiovascular Disease
Primary: Change in Vascular Inflammation — -3.8 percentage change
Phase 4 N=124 Moderate to Severe Plaque Psoriasis With Scalp Involvement
Psoriasis
Primary: Percentage Change From Baseline in Psoriasis Scalp Severity Index at Week 12 — 20.4; 86.8 Percent change — p=<0.0001
Phase 2 N=42 A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 13; 7; 20; 11 Participants
Phase 3 N=30 Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis
Psoriasis
Primary: Number of Participants With Clinical Improvement of Target Lesions — 18 Participants
Phase 4 N=12 A Study Evaluating the Efficacy and Tolerability of Oral Apremilast for the Treatment of Nail Psoriasis
Psoriatic Nail · Psoriasis Vulgaris · Psoriasis
Primary: Mean Percent Change of mNAPSI (Modified Nail Area Psoriasis Severity Index) at Week 36 Compared to Baseline for All Nails. — 64.1 percentage of reduction in mNAPSI score…
Phase 2 N=10 A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis
Plaque Psoriasis
Primary: Change From Baseline in the Psoriasis Area and Severity Index (PASI) — -4.3; -7.6; -8.0 score on a scale
Phase 1 N=29 A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
Psoriasis
Primary: Percentage (%) of Participants Who Achieved Greater Than or Equal (>=) to 75% Improvement From Baseline in Psoriasis Area Severity Index (PASI) Score at Week 12 — 5; 0…
Phase 2 N=275 AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
Plaque-type Psoriasis
Primary: Number of Participants With Adverse Events, Serious Adverse Events and Deaths — 44; 41; 180; 9 Participants
Phase 1 N=24 A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris
Psoriasis Vulgaris
Primary: Change in the Total Clinical Score From Baseline to Day 22 — -2.8; -1.9; -1.5; -1.8 units on a scale
N/A N=103 Improvement of Psoriasis Patients' Adherence to Topical Drugs
Psoriasis Vulgaris
Primary: Severity of Psoriasis — 2.68; 1.84 units on a scale
N/A N=660 Assessment of Long-Term Infliximab for Psoriasis (P05319)
Psoriasis
Primary: Number of Participants With a Psoriasis Area Sensitivity Index (PASI)-75 Response at Week 50 — 296 Participants
Phase 3 N=152 A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy
Plaque Psoriasis
Primary: Percentage of Participants Who Achieved an sPGA Score of Clear (0) or Almost Clear (1) at Week 16 — 43.7 percentage of participants
Phase 3 N=442 Twin Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis
Chronic Plaque Psoriasis
Primary: Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale — 99; 9 Participants — p=<0.0001
Phase 3 N=995 Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab
Moderate to Severe Plaque-type Psoriasis
Primary: Percent of Participants With Loss of Psoriasis Area and Severity Index (PASI) 75 Response up to Week 68 — 49.8; 25.4; 74.3; 64.7 Cummulative rate — p=<0.0001
Phase 2 N=176 Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy
Chronic Plaque Psoriasis
Primary: Achievement of Psoriasis Activity and Severity Index (PASI75) Response at Week 12 — 6.8; 74.6; 82.8 percentage of subjects — p=<0.001
Phase 3 N=182 Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque Psoriasis
Pediatric Plaque Psoriasis
Primary: Number of Participants With Adverse Events — 161; 149; 140; 14 participants
Phase 4 N=221 A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.
Parapsoriasis
Primary: Mean Percentage Change From Baseline in the Product of BSA (%) and the sPGA Which is Considered as the Total Psoriasis Severity Index at Week 16 — -10.17; -48.07…
Phase 3 N=763 Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)
Plaque Psoriasis
Primary: Number of Subjects With Adverse Events and Serious Adverse Events — 474; 19 Participants